Hanx Biopharmaceuticals Triggers Share Buyback; 23,000 H Shares Repurchased for HKD 0.68 Million

Bulletin Express04-17 20:07

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 17 April 2026.

Key details • Transaction size: 23,000 H shares, representing 0.017 % of the company’s 135.99 million issued shares (excluding treasury shares) prior to the transaction.

• Price range: HKD 28.80–30.80 per share, yielding a volume-weighted average cost of HKD 29.7647 per share.

• Aggregate consideration: HKD 0.68 million.

Post-transaction share capital • Issued shares outstanding (excluding treasury shares): 135.97 million. • Treasury shares on hand: 243,900 (increased from 220,900). • Total issued shares (including treasury stock): 136.22 million (unchanged, as repurchased shares are held in treasury).

Repurchase authority status • Current mandate: Up to 13.62 million shares authorised for repurchase by shareholder resolution dated 12 February 2026. • Cumulative repurchases under mandate: 243,900 shares, equivalent to 0.18 % of the issued share base on the mandate date. • Moratorium: Under HKEX rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 17 May 2026 (30 days after the latest repurchase).

All repurchases were conducted in accordance with Hong Kong Listing Rules and the company’s approved buyback mandate.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174704383?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174704383","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals Triggers Share Buyback; 23,000 H Shares Repurchased for HKD 0.68 Million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 17 April 2026.</p>\n<p>Key details  \n• Transaction size: 23,000 H shares, representing 0.017 % of the company’s 135.99 million issued shares (excluding treasury shares) prior to the transaction.</p>\n<p>• Price range: HKD 28.80–30.80 per share, yielding a volume-weighted average cost of HKD 29.7647 per share.</p>\n<p>• Aggregate consideration: HKD 0.68 million.</p>\n<p>Post-transaction share capital  \n• Issued shares outstanding (excluding treasury shares): 135.97 million.  \n• Treasury shares on hand: 243,900 (increased from 220,900).  \n• Total issued shares (including treasury stock): 136.22 million (unchanged, as repurchased shares are held in treasury).</p>\n<p>Repurchase authority status  \n• Current mandate: Up to 13.62 million shares authorised for repurchase by shareholder resolution dated 12 February 2026.  \n• Cumulative repurchases under mandate: 243,900 shares, equivalent to 0.18 % of the issued share base on the mandate date.  \n• Moratorium: Under HKEX rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 17 May 2026 (30 days after the latest repurchase).</p>\n<p>All repurchases were conducted in accordance with Hong Kong Listing Rules and the company’s approved buyback mandate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals Triggers Share Buyback; 23,000 H Shares Repurchased for HKD 0.68 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals Triggers Share Buyback; 23,000 H Shares Repurchased for HKD 0.68 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-17 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 17 April 2026.</p>\n<p>Key details  \n• Transaction size: 23,000 H shares, representing 0.017 % of the company’s 135.99 million issued shares (excluding treasury shares) prior to the transaction.</p>\n<p>• Price range: HKD 28.80–30.80 per share, yielding a volume-weighted average cost of HKD 29.7647 per share.</p>\n<p>• Aggregate consideration: HKD 0.68 million.</p>\n<p>Post-transaction share capital  \n• Issued shares outstanding (excluding treasury shares): 135.97 million.  \n• Treasury shares on hand: 243,900 (increased from 220,900).  \n• Total issued shares (including treasury stock): 136.22 million (unchanged, as repurchased shares are held in treasury).</p>\n<p>Repurchase authority status  \n• Current mandate: Up to 13.62 million shares authorised for repurchase by shareholder resolution dated 12 February 2026.  \n• Cumulative repurchases under mandate: 243,900 shares, equivalent to 0.18 % of the issued share base on the mandate date.  \n• Moratorium: Under HKEX rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 17 May 2026 (30 days after the latest repurchase).</p>\n<p>All repurchases were conducted in accordance with Hong Kong Listing Rules and the company’s approved buyback mandate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1174704383","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174704383","pubTimestamp":1776427629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药触发股票回购；以68万港元回购23,000股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market repurchase of 23,000 H shares on 17 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 17 April 2026.\nKey details  \n• Transaction size: 23,000 H shares, representing 0.017 % of the company’s 135.99 million issued shares (excluding treasury shares) prior to the transaction.\n• Price range: HKD 28.80–30.80 per share, yielding a volume-weighted average cost of HKD 29.7647 per share.\n• Aggregate consideration: HKD 0.68 million.\nPost-transaction share capital  \n• Issued shares outstanding (excluding treasury shares): 135.97 million.  \n• Treasury shares on hand: 243,900 (increased from 220,900).  \n• Total issued shares (including treasury stock): 136.22 million (unchanged, as repurchased shares are held in treasury).\nRepurchase authority status  \n• Current mandate: Up to 13.62 million shares authorised for repurchase by shareholder resolution dated 12 February 2026.  \n• Cumulative repurchases under mandate: 243,900 shares, equivalent to 0.18 % of the issued share base on the mandate date.  \n• Moratorium: Under HKEX rules, Hanx Biopharmaceuticals is restricted from issuing new shares or disposing of treasury shares until 17 May 2026 (30 days after the latest repurchase).\nAll repurchases were conducted in accordance with Hong Kong Listing Rules and the company’s approved buyback mandate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174704383","isCrawlerRequest":true}